vesatolimod

Small moleculeexperimental

Clinical trial activity

11 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
7
Phase 2
5
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 2012 (NCT01591668)

Timeline

2010s

  1. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2
Mol. weight
410.52 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • gs-9620
  • gs-9620
  • vesatolimod
  • vesatolimod
  • vesatolimod

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06071767Phase 1/Phase 2 (Phase 2)Jan 2, 2024Gilead Sciences, National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, University of Pittsburgh
NCT05458102Phase 1Aug 19, 2022Gilead Sciences
NCT05281510Phase 2Jun 9, 2022Gilead Sciences
NCT04364035Phase 2Feb 20, 2020Aelix Therapeutics, Autonomous University of Madrid, Gilead Sciences
NCT03060447Phase 1May 9, 2017Gilead Sciences
NCT02579382Phase 2Nov 10, 2015Gilead Sciences
NCT02858401Phase 1Jan 29, 2015Gilead Sciences
NCT02166047Phase 2Jun 1, 2014Gilead Sciences
NCT01590641Phase 1Apr 1, 2012Gilead Sciences
NCT01590654Phase 1Apr 1, 2012Gilead Sciences
NCT01591668Phase 1Mar 1, 2012Gilead Sciences
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Gilead SciencesFor profit11922012
Aelix TherapeuticsFor profit1112020
Autonomous University of MadridAcademic/Hospital1012020
National Institute of Allergy and Infectious Diseases (NIAID)Government1112024
University of OxfordAcademic/Hospital1012024
University of PittsburghAcademic/Hospital1012024
6 organizations
Page 1 / 1